About Taisho Pharmaceutical Group
Latest News
News
-
Group CompanyDecember 1, 2023
Products - Notification of the Approval of Home Self-injection Guidance and Management Fees and the Derestriction of the Dosing Period for NanozoraⓇ
-
Group CompanyAugust 1, 2023
R&D - Notification of Approval to Manufacture and Market Nanozora® 30mg Autoinjectors for S.C. Injection in Japan
-
Group CompanyJune 21, 2023
Corporate - Taisho Pharmaceutical and Biolinq Announce Strategic Collaboration and Exclusive License Agreement in Japan
-
Group CompanyDecember 1, 2022
Products - Launch of Nanozora® 30 mg Syringes for Subcutaneous Injection
-
Group CompanyNovember 24, 2022
Corporate - Transfer and Future Marketing of Osteoporosis Agent Bonviva in Japan
Investors
Stock Quote (TSE 1st: 4581)
